Single Dose of Clonazepam Versus Intermiittent Diazepam for Febrile Seizures Prevention

Sponsor
Queen Sirikit National Institute of Child Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT04364321
Collaborator
(none)
74
1
2
36.6
2

Study Details

Study Description

Brief Summary

To study the efficacy and safety of single dose clonazepam compared with intermittent oral diazepam for prevention of recurrent febrile seizures in children who had three or more febrile seizures.

Condition or Disease Intervention/Treatment Phase
  • Drug: Clonazepam 0.5 MG
  • Drug: Diazepam Tablets
N/A

Detailed Description

Febrile seizures are the most common type of seizures disorder of young children. The risk of recurrences are 33 percent overall, half of them had at least one recurrent seizure (the 3rd febrile seizures). After that the recurrent rate is 50-100 percent depend on their risk factors. A few studies found that multiple recurrent febrile seizures might associated with language developmental delayed, poor speed performance quotient, Attention deficit hyperactivity disorders. Moreover, seizures are upsetting both parents and children. During the febrile illness, the intermittent diazepam, continuous phenobarbital and valproate are effective for prevention of the recurrences. Because of the benign nature of a simple febrile seizures, the risks of side effects generally outweigh the benefits. However, there is no clinical guidelines for prevention of recurrent febrile seizures in the children who experienced multiple occurrences. The better prophylactic drug; safe, effective and easy to use, for prevention of recurrent febrile seizures in children with multiple recurrences might be needed. Clonazepam, the long half-life benzodiazepine, is commonly used for treatment of epilepsy may be effective in preventing recurrent febrile seizures. This study, a single-blind, randomized clinical trial, single dose clonazepam at the time of fever present compared with oral diazepam during the fever to prevent the recurrent febrile seizures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
74 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A pragmatic parallel group randomized trial comparing single dose clonazepam with intermittent oral diazepam for prevention recurrent febrile seizuresA pragmatic parallel group randomized trial comparing single dose clonazepam with intermittent oral diazepam for prevention recurrent febrile seizures
Masking:
Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
The Efficacy of A Single Dose Clonazepam Compared With the Intermittent Diazepam to Prevent Recurrent Febrile Seizures in Queen Sirikit National Institute of Child Health
Actual Study Start Date :
May 13, 2020
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Single dose Clonazepam

Clonazepam(0.5 mg/tablet) 0.02 mg/kg orally once at the time of fever present. (body temperature more than 38 degree Celsius)

Drug: Clonazepam 0.5 MG
Clonazepam 0.02 mg/kg only one dose
Other Names:
  • Rivotril
  • Povanil
  • Active Comparator: Intermittent oral diazepam

    Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr) start at the time of body temperature more than 38 degree Celsius.

    Drug: Diazepam Tablets
    Diazepam 0.3 mg/kg every 8 hours for 3 doses. (24 hr)

    Outcome Measures

    Primary Outcome Measures

    1. Recurrent rate of febrile seizures [the assessment will be done at 12 months after enrollment]

      Rate of seizure occurs when the children have febrile illnesses (at the onset of fever until fever gone). The seizures will be reported by their parents/caregivers. (via the seizure record form and the interview.) Statistic analysis: Cumulative incidence (person-year). percent. Comparison between the two group by unpaired t test.

    Secondary Outcome Measures

    1. Number of participants with adverse reaction of medications [7 days]

      The adverse reactions will be recorded by their caregivers in the record form for 7 days since patients taking the medication (clonapam or diazepam). The adverse reactions are drowsiness, ataxia, irritability, drooling, insomnia and rashes. Statistic analysis: cumulative incidence (person-year), Comparison between the two group by unpaired t test.

    2. Associated factors: Sex [at the enrollment.]

      To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by the primary investigator at the enrollment. Statistic analysis: comparison between group by chi square

    3. Associated factors: age at first febrile seizure [at the enrollment]

      To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers to recall the information. Statistic analysis: comparison between group by unpaired t test

    4. Associated factors: the lowest temperature that cause seizure [at the enrollment.]

      To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers to recall the information. Statistic analysis: comparison between group by unpaired t test

    5. Number of participants with febrile convulsions in parents or siblings [at the enrollment.]

      To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square

    6. Number of participants with epilepsy in parents or siblings [at the enrollment.]

      To evaluate the associated factors of multiple recurrent febrile seizures. The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square

    7. Number of participants with type of febrile seizures (simple or complex) [at the enrollment.]

      To evaluate the associated factors of multiple recurrent febrile seizures. Type of febrile seizure simple: seizure duration less than 15 min, generalized seizures, one seizure in 24 hours complex:15 minutes or more and/or focal seizures and/or 2 or more seizures in 24 hours The data will be collected in the record form by interviewing the caregivers. Statistic analysis: comparison between group by chi square

    8. Number of participants with delayed developmental milestones [at the enrollment.]

      The data will be collected by the developmental screening tools; Age and Stages Questionaires, third edition reported by the caregivers. Scoring will be done by neurology pediatrician at the enrollment. Age and Stages Questionaires(third editon) are divided in 5 areas; communication, gross motor, fine motor, problem solving, personal-social, each area has 6 questions. Scores for each area are between 0 to 60. The Cutoff points are different in each area. If the score is above the cutoff, the children development appears normal for age. (The cutoff for communication is 29.65, Gross motor is 22.25, fine motor is 25.14, problem solving is 27.72 and personal-social is 25.34) Statistic analysis: comparison between group by unpaired t test

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Months to 60 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • age 6-60 months at date of enrollment

    • 3 or more episodes of clinically diagnosed febrile seizures

    Exclusion Criteria:
    • history of afebrile seizures or any history suggested the epilepsy

    • history of previous brain insults; CNS infection, birth trauma, traumatic brain injury.

    • delayed developmental milestones

    • abnormal neurological examinations

    • currently treatment by continous antiepileptic drug(s)

    • A contraindication to Clonazepam, Diazepam such as drug hypersensitivity, liver disease.

    • Predictable lack of available of follow up.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Queen Sirikit National Institute of Child Health Ratchathewi Bangkok Thailand 10400

    Sponsors and Collaborators

    • Queen Sirikit National Institute of Child Health

    Investigators

    • Principal Investigator: Jinjutha Nithiuthai, MD, Queen Sirikit National Institute of Child Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Kullasate Sakpichaisakul, Director of Pediatric Neurology, Queen Sirikit National Institute of Child Health
    ClinicalTrials.gov Identifier:
    NCT04364321
    Other Study ID Numbers:
    • QSNICH63-017
    First Posted:
    Apr 28, 2020
    Last Update Posted:
    Aug 30, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Kullasate Sakpichaisakul, Director of Pediatric Neurology, Queen Sirikit National Institute of Child Health
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 30, 2021